Big relief: Britain has opened doors for those taking Covaxin from today, the problem of being quarantined also ends - Politics news of India | Current politics news | Politics news from India | Trending politics news,India News (भारत समाचार): India News,world news, India Latest And Breaking News, United states of amerika, united kingdom

.

Monday, November 22, 2021

Big relief: Britain has opened doors for those taking Covaxin from today, the problem of being quarantined also ends

Britain has approved Covaxin, a corona vaccine manufactured by Bharat Biotech. People taking India's indigenous vaccine no longer need to be quarantined in the United Kingdom. Earlier Britain had not approved this vaccine.
Britain has given great relief for people who have taken India's indigenous corona vaccine Covaxin. From today, Britain has allowed people taking Covaxin to come here. Britain has added India's Covaxin to its list of approved vaccines. From 22 November, travelers getting the Bharat Biotech-made vaccine will no longer have to be quarantined in the United Kingdom. Let us tell you that after the approval of the World Health Organization (WHO), Britain had announced the green signal to Covaxin.

This decision of Britain will bring relief to thousands of Indian travelers who have taken Covaxin and were waiting for permission. The UK government has included Covaxin as well as China's Sinovac and Sinopharm vaccines in the list of approved vaccines.

Got approval from today

Covaxin is the second largest vaccine used in India. Earlier, passengers who had been vaccinated had to remain in quarantine after going to the United Kingdom, but the rules came into force from 4 am on November 22 and will no longer be so.

77.8 percent effect of Covaxin

Let us tell you that its effect has shown good on corona patients who have applied Covaxin. According to government data, this vaccine has shown 77.8 percent effect on corona patients. It is 65.2 percent effective against the new delta form of the virus. The company said in June that it had conducted a final analysis of Covaxin's effectiveness from Phase III trials.